Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ATNF 180 Life Sciences Corp
- Stocks
- Healthcare
- NASDAQ: ATNF
Price (delayed)
$1.18
Market cap
$6.72M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$14.76
Enterprise value
$3.15M
180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined
Highlights
ATNF's debt has dropped by 81% year-on-year
ATNF's EPS is up by 50% year-on-year and by 4.7% since the previous quarter
180 Life Sciences's net income has surged by 54% YoY but it has decreased by 21% QoQ
The quick ratio has declined by 28% since the previous quarter
180 Life Sciences's equity has decreased by 17% from the previous quarter
Key stats
What are the main financial stats of ATNF
Market
Valuations
Earnings
Shares outstanding
5.7M
Market cap
$6.72M
Enterprise value
$3.15M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.79
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$6.61M
Net income
-$7.47M
EBIT
-$7.73M
EBITDA
-$7.69M
Free cash flow
-$1.3M
Per share
Balance sheet
Liquidity
EPS
-$14.76
EPS diluted
-$14.76
Free cash flow per share
-$0.37
Book value per share
$1.49
Revenue per share
$0
TBVPS
$1.14
Total assets
$11.65M
Total liabilities
$3.95M
Debt
$151,816
Equity
$7.71M
Working capital
$86,956
Debt to equity
0.02
Current ratio
1.02
Quick ratio
0.94
Net debt/EBITDA
0.46
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-159.6%
Return on equity
-305.4%
Return on invested capital
N/A
Return on capital employed
-100.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ATNF stock price
How has the 180 Life Sciences stock price performed over time
Intraday
0.85%
1 week
8.26%
1 month
34.52%
1 year
-28.48%
YTD
-35.16%
QTD
20.4%
Financial performance
How have 180 Life Sciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$6.61M
Net income
-$7.47M
Gross margin
N/A
Net margin
N/A
180 Life Sciences's net income has surged by 54% YoY but it has decreased by 21% QoQ
180 Life Sciences's operating income has increased by 39% YoY but it has decreased by 4.4% QoQ
Price vs fundamentals
How does ATNF's price correlate with its fundamentals
Growth
What is 180 Life Sciences's growth rate over time
Valuation
What is 180 Life Sciences stock price valuation
P/E
N/A
P/B
0.79
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ATNF's EPS is up by 50% year-on-year and by 4.7% since the previous quarter
The price to book (P/B) is 89% lower than the 5-year quarterly average of 7.0
180 Life Sciences's equity has decreased by 17% from the previous quarter
Efficiency
How efficient is 180 Life Sciences business performance
180 Life Sciences's return on equity has surged by 74% YoY and by 37% QoQ
The company's return on assets rose by 33% YoY and by 14% QoQ
Dividends
What is ATNF's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ATNF.
Financial health
How did 180 Life Sciences financials performed over time
The company's total assets is 195% higher than its total liabilities
The current ratio has soared by 127% YoY but it has contracted by 31% from the previous quarter
The quick ratio has declined by 28% since the previous quarter
ATNF's debt is 98% smaller than its equity
ATNF's debt to equity has soared by 102% year-on-year
ATNF's debt has dropped by 81% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.